Inactivation of AR/TMPRSS2-ERG/Wnt signaling networks attenuates the aggressive behavior of prostate cancer cells

Cancer Prevention Research

Volumn 4, Issue 9, 2011, Pages 1495-1506

  Li, Yiwei ^a   Kong, Dejuan ^a   Wang, Zhiwei ^a   Ahmad, Aamir ^a   Bao, Bin ^a   Padhye, Subhash ^b   Sarkar, Fazlul H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Abeda Inamdar Senior College   (India)

Author keywords

[No Author keywords available]

Indexed keywords

3,3' DIINDOLYLMETHANE; 3,3' DIINDOLYLMETHANE DERIVATIVE; ANDROGEN RECEPTOR; CURCUMIN; CURCUMIN DERIVATIVE; UNCLASSIFIED DRUG; WNT PROTEIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CANCER INVASION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG MECHANISM; FUSION GENE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN INDUCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION;

APOPTOSIS; BIOLOGICAL AVAILABILITY; CELL PROLIFERATION; CYTOPLASM; HUMANS; IMMUNOPRECIPITATION; MALE; NEOPLASM INVASIVENESS; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; SERINE ENDOPEPTIDASES; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSFECTION; WNT PROTEINS;

EID: 80052576657     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-11-0077     Document Type: Article

References (48)

1. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
2. Sircar K., Yoshimoto M., Monzon F.A., Koumakpayi I.H., Katz R.L., Khanna A., et al. PTEN genomic deletion is associated with p-Akt and AR signalling in poorer outcome, hormone refractory prostate cancer. J Pathol 2009;218:505-513
3. de la TA, Rubin MA, Chen MW, Vacherot F, de Medina SG, Burchardt M, et al. Beta-catenin-related anomalies in apoptosis-resistant and hormone-refractory prostate cancer cells. Clin Cancer Res 2003; 9:1801-1807
4. Azoulay S., Terry S., Chimingqi M., Sirab N., Faucon H, Gil Diez de MS, et al. Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression. J Pathol 2008;216:460-470
5. Donovan M.J., Osman I., Khan F.M., Vengrenyuk Y., Capodieci P., Koscuiszka M., et al. Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU Int 2009;105:462-467
6. Kawata H., Ishikura N., Watanabe M., Nishimoto A., Tsunenari T., Aoki Y. Prolonged treatment with bicalutamide induces androgen receptor overexpression and androgen hypersensitivity. Prostate 2010;70: 745-754
7. Waltering K.K., Helenius M.A., Sahu B., Manni V., Linja M.J., Janne O.A., et al. Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens. Cancer Res 2009;69:8141-8149
8. Tomlins S.A., Rhodes D.R., Perner S., Dhanasekaran S.M., Mehra R., Sun X.W., et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648 (Pubitemid 41528150)
9. Nam R.K., Sugar L., Yang W., Srivastava S., Klotz L.H., Yang L.Y., et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007;97:1690-1695 (Pubitemid 350249347)
10. Klezovitch O., Risk M., Coleman I., Lucas J.M., Null M., True L.D., et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A 2008;105:2105-2110 (Pubitemid 351439472)
11. Rajput A.B., Miller M.A., De L.A., Boyd N., Leung S., Hurtado-Coll A., et al. Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers. J Clin Pathol 2007; 60:1238-1243 (Pubitemid 350084545)
12. Carver B.S., Tran J., Gopalan A., Chen Z., Shaikh S., Carracedo A., et al. Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet 2009;41:619-624
13. King J.C., Xu J., Wongvipat J., Hieronymus H., Carver B.S., Leung D.H., et al. Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet 2009;41:524-6. 14.
14. Iljin K., Wolf M., Edgren H., Gupta S., Kilpinen S., Skotheim R.I., et al. TMPRSS2 fusions with oncogenic ETS factors in prostate cancer involve unbalanced genomic rearrangements and are associated with HDAC1 and epigenetic reprogramming. Cancer Res 2006;66: 10242-10246 (Pubitemid 44799738)
15. Cai C., Wang H., Xu Y., Chen S., Balk S.P. Reactivation of androgen receptor-regulated TMPRSS2:ERG gene expression in castrationresistant prostate cancer. Cancer Res 2009;69:6027-6032
16. Gupta S., Iljin K., Sara H., Mpindi J.P., Mirtti T., Vainio P., et al. FZD4 as a mediator of ERG oncogene-induced WNT signaling and epithelial-tomesenchymal transition in human prostate cancer cells. Cancer Res 2010;70:6735-6745
17. Yu JYu J, Mani RS, Cao Q, Brenner CJ, Cao X, et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell 2010;17: 443-454
18. Hermans K.G., Boormans J.L., Gasi D., Van Leenders G.J., Jenster G., Verhagen P.C., et al. Overexpression of prostate-specific TMPRSS2 (exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res 2009;15:6398-6403
19. Yang X., Chen M.W., Terry S., Vacherot F., Bemis D.L., Capodice J., et al. Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells. Oncogene 2006;25:3436-3444 (Pubitemid 43877046)
20. Klaus A., Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008;8:387-398 (Pubitemid 351589714)
21. Chen G., Shukeir N., Potti A., Sircar K., Aprikian A., Goltzman D., et al. Upregulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: Potential pathogenetic and prognostic implications. Cancer 2004;101:1345-1356 (Pubitemid 39180390)
22. Terry S., Yang X., Chen M.W., Vacherot F., Buttyan R. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer. J Cell Biochem 2006;99:402-410 (Pubitemid 44435558)
23. Li Y., Wang Z., Kong D., Murthy S., Dou Q.P., Sheng S., et al. Regulation of FOXO3a/beta-catenin/GSK-3beta signaling by 3,30-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in prostate cancer cells. J Biol Chem 2007;282:21542-21550 (Pubitemid 47099972)
24. Tsui K.H., Feng T.H., Lin C.M., Chang P.L., Juang H.H. Curcumin blocks the activation of androgen and interlukin-6 on prostate-specific antigen expression in human prostatic carcinoma cells. J Androl 2008;29: 661-668
25. Ryu M.J., Cho M., Song J.Y., Yun Y.S., Choi I.W., Kim D.E., et al. Natural derivatives of curcumin attenuate the Wnt/beta-catenin pathway through down-regulation of the transcriptional coactivator p300. Biochem Biophys Res Commun 2008;377:1304-1308
26. Anand P., Kunnumakkara A.B., Newman R.A., Aggarwal B.B. Bioavailability of curcumin: Problems and promises. Mol Pharm 2007;4: 807-818
27. Garcea G., Berry D.P., Jones D.J., Singh R., Dennison A.R., Farmer P.B., et al. Consumption of the putative chemopreventive agent curcumin by cancer patients: Assessment of curcumin levels in the colorectum and their pharmacodynamic consequences. Cancer Epidemiol Biomarkers Prev 2005;14:120-125 (Pubitemid 40165291)
28. Padhye S., Banerjee S., Chavan D., Pandye S., Swamy K.V., Ali S., et al. Fluorocurcumins as cyclooxygenase-2 inhibitor: molecular docking, pharmacokinetics and tissue distribution in mice. Pharm Res 2009;26:2438-45.
29. Anderton MJ, Manson MM, Verschoyle R, Gescher A, Steward WP, Williams ML, et al. Physiological modeling of formulated and crystalline 3,30-diindolylmethane pharmacokinetics following oral administration in mice. Drug Metab Dispos 2004;32:632-638
30. Li Y., Ahmed F., Ali S., Philip P.A., Kucuk O., Sarkar F.H. Inactivation of nuclear factor kappaB by soy isoflavone genistein contributes to increased apoptosis induced by chemotherapeutic agents in human cancer cells. Cancer Res 2005;65:6934-6942 (Pubitemid 41060733)
31. Levy L., Wei Y., Labalette C., Wu Y., Renard C.A., Buendia M.A., et al. Acetylation of beta-catenin by p300 regulates beta-catenin-Tcf4 interaction. Mol Cell Biol 2004;24:3404-3414 (Pubitemid 38452083)
32. Takemaru K.I., Moon R.T. The transcriptional coactivator CBP interacts with beta-catenin to activate gene expression. J Cell Biol 2000; 149:249-254 (Pubitemid 30227143)
33. Bhuiyan M.M., Li Y., Banerjee S., Ahmed F., Wang Z., Ali S., et al. Downregulation of androgen receptor by 3,30-diindolylmethane contributes to inhibition of cell proliferation and induction of apoptosis in both hormone-sensitive LNCaP and insensitive C4-2B prostate cancer cells. Cancer Res 2006;66:10064-10072 (Pubitemid 44672060)
34. Mani R.S., Tomlins S.A., Callahan K., Ghosh A., Nyati M.K., Varambally S., et al. Induced chromosomal proximity and gene fusions in prostate cancer. Science 2009;326:1230.
35. Haffner M.C., Aryee M.J., Toubaji A., Esopi D.M., Albadine R., Gurel B., et al. Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangements. Nat Genet 2010;42:668-675
36. Lin C., Yang L., Tanasa B., Hutt K., Ju B.G., Ohgi K., et al. Nuclear receptor-induced chromosomal proximity and DNA breaks underlie specific translocations in cancer. Cell 2009;139:1069-1083
37. Bastus N.C., Boyd L.K., Mao X., Stankiewicz E., Kudahetti S.C., Oliver R.T., et al. Androgen-induced TMPRSS2:ERG fusion in nonmalignant prostate epithelial cells. Cancer Res 2010;70:9544-9548
38. Perner S., Svensson M.A., Hossain R.R., Day J.R., Groskopf J., Slaughter R.C., et al. ERG rearrangement metastasis patterns in locally advanced prostate cancer. Urology 2010;75:762-767
39. Nam R.K., Sugar L., Wang Z., Yang W., Kitching R., Klotz L.H., et al. Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther 2007;6:40-45 (Pubitemid 46294173)
40. Wang J., Cai Y., Yu W., Ren C., Spencer D.M., Ittmann M. Pleiotropic biological activities of alternatively spliced TMPRSS2/ERG fusion gene transcripts. Cancer Res 2008;68:8516-8524
41. Perner S., Mosquera J.M., Demichelis F., Hofer M.D., Paris P.L., Simko J., et al. TMPRSS2-ERG fusion prostate cancer: An early molecular event associated with invasion. Am J Surg Pathol 2007;31:882-888 (Pubitemid 47165141)
42. Li X., Placencio V., Iturregui J.M., Uwamariya C., Sharif-Afshar A.R., Koyama T., et al. Prostate tumor progression is mediated by a paracrine TGF-beta/Wnt3a signaling axis. Oncogene 2008;27:7118-7130
43. Yu X., Wang Y., Degraff D.J., Wills M.L., Matusik R.J. Wnt/beta-Catenin activation promotes prostate tumor progression in a mouse model. Oncogene 2010;30:1868-1879
44. Uysal-Onganer P., Kawano Y., Caro M., Walker M.M., Diez S., Darrington R.S., et al. Wnt-11 promotes neuroendocrine-like differentiation, survival and migration of prostate cancer cells. Mol Cancer 2010;9:55.
45. Thompson V.C., Hurtado-Coll A., Turbin D., Fazli L., Lehman M.L., Gleave M.E., et al. Relaxin drives Wnt signaling through upregulation of PCDHY in prostate cancer. Prostate 2010;70:1134-1145
46. Hawksworth D., Ravindranath L., Chen Y., Furusato B., Sesterhenn I.A., McLeod D.G., et al. Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence. Prostate Cancer Prostatic Dis 2010;13:311-315
47. Cho H.J., Oh Y.J., Kwon J., Kwon J.Y., Kim K.S., Kim H. c-Myc stimulates cell invasion by inhibiting FBX8 function. Mol Cells 2010;30:355-362
48. Chuan Y.C., Iglesias-Gato D., Fernandez-Perez L., Cedazo-Minguez A., Pang S.T., Norstedt G., et al. Ezrin mediates c-Myc actions in prostate cancer cell invasion. Oncogene 2010;29:1531-1542